Table 2.
ANC recovery in Induction 1 and Consolidation
| Pegfilgrastim 6 mg (n = 42) | Filgrastim 5 μg/kg/day (n = 41) | |
| Induction 1 | ||
| Number of patients starting cycle | 42 | 41 |
| Number of patients (%) with SN | 42 (100%) | 41 (100%) |
| Number of patients (%) with ANC recoverya | 35 (83%) | 32 (78%) |
| Median time to ANC recoveryb | 22 days | 22 days |
| Range | 16, 55 | 19, 62 |
| Difference between medians (95% CI) | 0.0 (-1.9 to 1.9) | |
| Consolidation | ||
| Number of patients starting cycle | 22 | 24 |
| Number of patients (%) with SN | 20 (91%) | 21 (88%) |
| Number of patients (%) with ANC recoverya | 18 (82%) | 23 (96%) |
| Median time to ANC recoveryb | 17 days | 16.5 days |
| Range | 1, 57 | 1, 51 |
| Difference between medians (95% CI) | 0.5 (-1.1 to 2.1) | |
ANC, absolute neutrophil count; SN, severe neutropenia (ANC <0.5 × 109/L); CI, confidence interval.
aIncludes patients whose ANC remained at or above 0.5 × 109/L
bNumber of days from start of chemotherapy until the first of 2 consecutive days with ANC ≥ 0.5 × 109/L; time to recovery was set to 1 day for patients whose ANC remained at or above 0.5 × 109/L